SCHEMBL15840765

SCHEMBL15840765

Cc1cccc(Cc2c(C)nc(Nc3nc(C)c4cccc(C)c4n3)[nH]c2=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
MAPT P10636 5/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
STAT3 P40763 2/20 0.51
RAB9A P51151 3/20 0.45
USP2 O75604 2/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.43
STAT1 P42224 1/20 0.43
TSHR P16473 1/20 0.42
HSD17B10 Q99714 2/20 0.42
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
AURKA O14965 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840690 0.91 ALDH1A1 (0.55) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840587 0.82 MAPT (0.52) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840687 0.81 ALDH1A1 (0.50) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840698 0.77 AURKA (0.46) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL23657581 0.75 ALDH1A1 (0.60) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840763 0.72 ALDH1A1 (0.62) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840753 0.72 STAT3 (0.71) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840775 0.71 ALDH1A1 (0.70) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840784 0.71 MAPT (0.56) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3
SCHEMBL15840786 0.70 MAPT (0.60) ALDH1A1MAPTKMT2ASMN1; SMN2STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 ALDH1A1 4348/4885MAPT 1076/4885KMT2A 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.